Shares of leading organ transplant platform TransMedics (NASDAQ: TMDX) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence .
The S&P 500 Index ($SPX ) (SPY ) today is down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.23%. Stocks today are posting...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.09%. Stocks today are slightly...
TransMedics Group TMDX is a key player in transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The company offers Organ Care System, an integrated, compact,...
This growth stock has been on my watchlist for a while and might soon be included in my portfolio.
Growth investors have seen their fair share of bumps in the road the last few years, with some great businesses they follow being forced to navigate some real challenges. Several of these growth stocks...
This organ transplant specialist is down, but still has plenty of signs of life.
Sales growth is tapering off for this provider of delivery services for transplant organs.
The organ transplant specialist posted disappointing results in its third-quarter report.
TransMedics quickly became the leader in liver, heart, and lung transplants, but its third-quarter earnings left the market worried. Here's why I believe its pullback in share price is an opportunity.